End-of-life chemotherapy use at a Finnish university hospital: a retrospective cohort study. (3rd October 2017)

• Record Type: Journal Article
• Authors: Rautakorpi, Liisa K.; Seyednasrollah, Fatemeh; Mäkelä, Johanna M.; Hirvonen, Outi M.; Laitinen, Tarja; Elo, Laura L.; Jyrkkiö, Sirkku M.
• Is Part Of: Acta oncologica. Volume 56:Number 10(2017)
• Page Start: 1272
• Page End: 1276
• Publication Date: 2017-10-03
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2017.1332424
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: Recent trends in the end-of-life (EOL) cancer care have suggested that the levels of treatment are becoming more aggressive. The aim of this single-center study was to evaluate the time from the last intravenous (IV) chemotherapy treatment to death and identify factors correlating with treatment closer to death. Material and methods: The study included all patients diagnosed with cancer at Turku University Central Hospital between the years 2005 and 2013 ( N = 38, 982) who received IV chemotherapy during the last year of life ( N = 3285). The cohort of patients and their respective clinical information were identified from electronic medical records. Statistical analysis was performed to assess and compare the treatment strategies, taking into account the patient's age, the year they were treated, and the type of cancer they were diagnosed with. Results: A total of 11, 250 cancer patients died during the observation time and one-third ( N = 3285, 29.2%) of them had received IV chemotherapy during the last year of life. The time from the last IV chemotherapy regimen to death remained consistent across the follow-up time. During the last month of life, every third patient under the age of 50 years and only one-tenth of patients over the age of 80 years received IV chemotherapy. Hematological malignancies and lymphomas were treated closer to death when compared to other diagnostic groups. Conclusions: During the period of 9 years, the pattern of EOL IV chemotherapy treatment remained stable. Every third patient died at tertiary care. Only 7.2% of patients who received IV chemotherapy during the last year of life were treated 14 days before death, which is in line with international recommendations. However, significant variation in EOL treatment strategies between different diagnosis and age groups were identified.